RYR1 and melanoma: We assessed synergistic effects of CcO inhibition and plasma-treated medium in murine B16F0 (non-metastatic), B16F10 (metastatic)28,29, and human SK-MEL-28 (BRAF+) melanoma cells as well non-malignant human HaCaT keratinocytes.